PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34536949-2 2021 We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to ADT will further reduce the duration of treatment exposure by prolonging time to prostate-specific antigen (PSA) recurrence without impacting eugonad state recovery. Abiraterone Acetate 37-56 kallikrein related peptidase 3 Homo sapiens 172-197 34944964-8 2021 In conclusion, sarcopenia is an independent prognostic factor for poor FFS and time to PSA progression in patients with mHSPC who receive early docetaxel or abiraterone acetate treatment. Abiraterone Acetate 157-176 kallikrein related peptidase 3 Homo sapiens 87-90 34536949-2 2021 We hypothesised that finite-duration abiraterone acetate plus prednisone (Abi +P) added to ADT will further reduce the duration of treatment exposure by prolonging time to prostate-specific antigen (PSA) recurrence without impacting eugonad state recovery. Abiraterone Acetate 37-56 kallikrein related peptidase 3 Homo sapiens 199-202 31183025-1 2019 A 66-year-old man with a previous history of advanced prostate cancer failing complete androgen blockade, docetaxel chemotherapy, denosumab, and abiraterone acetate as judged by persistent high serum levels of prostate specific antigen presented with exertional dyspnea, normocytic anemia, and thrombocytopenia. Abiraterone Acetate 145-164 kallikrein related peptidase 3 Homo sapiens 210-235 33571020-1 2021 OBJECTIVES: To quantify the association between dose reductions of abiraterone acetate plus prednisone (AAP) or enzalutamide and prostate-specific antigen (PSA) progression in patients with metastatic castration-resistant prostate cancer (mCRPC). Abiraterone Acetate 67-86 kallikrein related peptidase 3 Homo sapiens 129-154 33324967-2 2021 METHODS: Patients with early metastatic castration-resistant prostate cancer with confirmed prostate-specific antigen progression within 1-year or prostate-specific antigen progression without having normal prostate-specific antigen level (<4.0 ng/mL) during first-line androgen deprivation therapy were enrolled and administered abiraterone acetate (1000 mg) plus prednisolone (10 mg). Abiraterone Acetate 330-349 kallikrein related peptidase 3 Homo sapiens 92-117 33650292-0 2021 Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. Abiraterone Acetate 172-191 kallikrein related peptidase 3 Homo sapiens 22-26 32791510-2 2021 METHODS: This study included postdocetaxel patients with mCRPC treated with abiraterone acetate combined with prednisone (AA + P) who had experienced prostate-specific antigen (PSA) progression. Abiraterone Acetate 76-95 kallikrein related peptidase 3 Homo sapiens 150-175 33116879-0 2020 PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate. Abiraterone Acetate 133-152 kallikrein related peptidase 3 Homo sapiens 0-3 32291107-1 2020 Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. Abiraterone Acetate 179-198 kallikrein related peptidase 3 Homo sapiens 15-40 33980956-5 2021 Abiraterone acetate therapy and Gleason score were significant independent factors of PSA-PFS. Abiraterone Acetate 0-19 kallikrein related peptidase 3 Homo sapiens 86-89 33980956-8 2021 Abiraterone acetate therapy and Gleason score were significant independent factors for PSA-PFS in matched patients. Abiraterone Acetate 0-19 kallikrein related peptidase 3 Homo sapiens 87-90 33980956-9 2021 The PSA-PFS and OS of patients treated with abiraterone acetate in combination with a GnRH antagonist were significantly better than those treated with bicalutamide. Abiraterone Acetate 44-63 kallikrein related peptidase 3 Homo sapiens 4-7 30194199-0 2018 Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate. Abiraterone Acetate 100-119 kallikrein related peptidase 3 Homo sapiens 79-82 30194199-1 2018 BACKGROUND/AIM: The main purpose of this study was to evaluate the outcome of patients with prostate-specific antigen (PSA) progression after abiraterone acetate (AA) treatment for metastatic castration-resistant prostate cancer (mCRPC). Abiraterone Acetate 142-161 kallikrein related peptidase 3 Homo sapiens 92-123 29630978-0 2018 The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. Abiraterone Acetate 29-48 kallikrein related peptidase 3 Homo sapiens 67-92 29630978-15 2018 CONCLUSIONS: In patients with high risk, nonmetastatic, castration resistant prostate cancer treatment with abiraterone acetate plus prednisone demonstrated a significant 50% or greater prostate specific antigen reduction with encouraging results for the secondary end points, including the safety of 5 mg prednisone. Abiraterone Acetate 108-127 kallikrein related peptidase 3 Homo sapiens 186-211 29725416-0 2018 Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. Abiraterone Acetate 67-86 kallikrein related peptidase 3 Homo sapiens 9-34 28744160-1 2017 Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with improvement in overall survival as well as secondary end points such as prostate-specific antigen (PSA) and radiographic response rates, time to PSA progression, and progression-free survival. Abiraterone Acetate 0-19 kallikrein related peptidase 3 Homo sapiens 367-398 28358937-11 2017 Main Outcomes and Measures: The primary end point was a PSA level of 0.2 ng/mL or lower within 12 months of starting abiraterone acetate plus prednisone. Abiraterone Acetate 117-136 kallikrein related peptidase 3 Homo sapiens 56-59 28744160-1 2017 Abiraterone acetate has established a major role in the treatment paradigm of metastatic castration-resistant prostate cancer ever since pivotal trials, COU-AA-301 and COU-AA-302, have shown benefit in both the second-line and first-line (post- and pre-chemotherapy) setting, respectively, with improvement in overall survival as well as secondary end points such as prostate-specific antigen (PSA) and radiographic response rates, time to PSA progression, and progression-free survival. Abiraterone Acetate 0-19 kallikrein related peptidase 3 Homo sapiens 394-397 28126272-0 2017 Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. Abiraterone Acetate 76-95 kallikrein related peptidase 3 Homo sapiens 0-25 27324190-1 2017 BACKGROUND AND OBJECTIVES: Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) and supported PSA dynamics as bridging surrogacy endpoints for clinical benefit from treatment with abiraterone acetate plus prednisone. Abiraterone Acetate 306-325 kallikrein related peptidase 3 Homo sapiens 80-111 27601278-0 2017 Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer. Abiraterone Acetate 54-73 kallikrein related peptidase 3 Homo sapiens 0-25 27489290-0 2017 Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Abiraterone Acetate 88-107 kallikrein related peptidase 3 Homo sapiens 25-50 27324190-6 2017 RESULTS: A tumor growth inhibition model best described PSA dynamics post-treatment with abiraterone acetate. Abiraterone Acetate 89-108 kallikrein related peptidase 3 Homo sapiens 56-59 27324190-7 2017 Abiraterone acetate treatment in chemotherapy-pretreated and chemotherapy-naive patients increased the PSA decay rate (k dec) to the same extent (1.28-fold, 95 % confidence interval [CI] 0.58-1.98; and 0.93-fold, 95 % CI 0.6-1.27, respectively). Abiraterone Acetate 0-19 kallikrein related peptidase 3 Homo sapiens 103-106 27324190-11 2017 CONCLUSION: The model appropriately described the exposure-response relationship between abiraterone and PSA dynamics in chemotherapy-pretreated and chemotherapy-naive patients following oral administration of abiraterone acetate. Abiraterone Acetate 210-229 kallikrein related peptidase 3 Homo sapiens 105-108 27324190-1 2017 BACKGROUND AND OBJECTIVES: Recent analysis revealed strong associations between prostate-specific antigen (PSA) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) and supported PSA dynamics as bridging surrogacy endpoints for clinical benefit from treatment with abiraterone acetate plus prednisone. Abiraterone Acetate 306-325 kallikrein related peptidase 3 Homo sapiens 107-110 25981621-7 2015 We performed correlation analysis between previous prostate-specific antigen response to abiraterone acetate and subsequent prostate-specific antigen response to docetaxel. Abiraterone Acetate 89-108 kallikrein related peptidase 3 Homo sapiens 51-76 26965561-3 2016 OBJECTIVE: To evaluate the association between early PSA decline and OS following abiraterone acetate (AA) treatment. Abiraterone Acetate 82-101 kallikrein related peptidase 3 Homo sapiens 53-56 26965561-17 2016 Our data suggest that early PSA changes are associated with survival in patients receiving abiraterone acetate. Abiraterone Acetate 91-110 kallikrein related peptidase 3 Homo sapiens 28-31 26879374-3 2016 RESULTS: Abiraterone acetate-prednisone treatment significantly decreased prostate-specific antigen progression risk by 49%, with longer median time to prostate-specific antigen progression of 5.55 months versus 2.76 months in the placebo-prednisone group (hazard ratio 0.506, P = 0.0001, primary end-point). Abiraterone Acetate 9-28 kallikrein related peptidase 3 Homo sapiens 74-99 26879374-3 2016 RESULTS: Abiraterone acetate-prednisone treatment significantly decreased prostate-specific antigen progression risk by 49%, with longer median time to prostate-specific antigen progression of 5.55 months versus 2.76 months in the placebo-prednisone group (hazard ratio 0.506, P = 0.0001, primary end-point). Abiraterone Acetate 9-28 kallikrein related peptidase 3 Homo sapiens 152-177 27150425-8 2016 RESULTS: Six single nucleotide polymorphisms in the estrogen sulfotransferase gene SULT1E1 were associated with time to treatment failure on abiraterone acetate therapy after false discovery rate (q value) correction for multiple testing while controlling for Gleason score, age, level of alkaline phosphatase and prostate specific antigen at treatment initiation (q <0.05). Abiraterone Acetate 141-160 kallikrein related peptidase 3 Homo sapiens 314-339 27278777-0 2016 Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials. Abiraterone Acetate 64-83 kallikrein related peptidase 3 Homo sapiens 21-24 27278777-0 2016 Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials. Abiraterone Acetate 64-83 kallikrein related peptidase 3 Homo sapiens 45-48 25981621-7 2015 We performed correlation analysis between previous prostate-specific antigen response to abiraterone acetate and subsequent prostate-specific antigen response to docetaxel. Abiraterone Acetate 89-108 kallikrein related peptidase 3 Homo sapiens 124-149 25981621-14 2015 The prostate-specific antigen response to previous abiraterone acetate could not predict the efficacy of subsequent docetaxel. Abiraterone Acetate 51-70 kallikrein related peptidase 3 Homo sapiens 4-29 25829400-0 2015 Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Abiraterone Acetate 79-98 kallikrein related peptidase 3 Homo sapiens 20-45 24971430-0 2014 PSA flare after initiation of abiraterone acetate. Abiraterone Acetate 30-49 kallikrein related peptidase 3 Homo sapiens 0-3 25320340-6 2014 RESULTS: A confirmed prostate-specific antigen response was observed in 29/48 (60.4%) patients by week 12; lower limit of two-sided 90% confidence interval was >35% (threshold response rate), demonstrating efficacy of abiraterone acetate. Abiraterone Acetate 221-240 kallikrein related peptidase 3 Homo sapiens 21-46 25320340-11 2014 CONCLUSIONS: Efficacy of abiraterone acetate plus prednisolone was demonstrated by decline in prostate-specific antigen levels with evidence of antitumor activity by radiography in Japanese patients with chemotherapy-naive metastatic castration-resistant prostate cancer. Abiraterone Acetate 25-44 kallikrein related peptidase 3 Homo sapiens 94-119 24941984-0 2014 Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. Abiraterone Acetate 96-115 kallikrein related peptidase 3 Homo sapiens 25-50 24210911-0 2014 Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome? Abiraterone Acetate 72-91 kallikrein related peptidase 3 Homo sapiens 14-39 24458472-0 2014 Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Abiraterone Acetate 51-70 kallikrein related peptidase 3 Homo sapiens 35-38 23023354-4 2012 Multiple randomized trials have shown significant improvement of >50% decline in prostate-specific antigen (PSA) and time to PSA progression (TTPP) with abiraterone acetate 1000 mg per day in chemotherapy/ketoconazole treated and naive CRPC patients producing reversible and manageable adverse effects due to mineralocorticoid excess. Abiraterone Acetate 156-175 kallikrein related peptidase 3 Homo sapiens 111-114 21984773-4 2011 In the area of androgen depletion, abiraterone acetate and MDV100 have been studied and have shown to decrease prostate-specific antigen (PSA) levels in phase I and II studies. Abiraterone Acetate 35-54 kallikrein related peptidase 3 Homo sapiens 111-142 20159824-3 2010 This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics, and effects on steroidogenesis and prostate-specific antigen (PSA) levels in men with CPRC with or without prior ketoconazole therapy. Abiraterone Acetate 38-57 kallikrein related peptidase 3 Homo sapiens 129-160 19470933-11 2009 CONCLUSION: CYP17 blockade by abiraterone acetate results in declines in PSA and CTC counts and radiologic responses, confirming that CRPC commonly remains hormone driven. Abiraterone Acetate 30-49 kallikrein related peptidase 3 Homo sapiens 73-76